Liraglutide
Price on application
Liraglutide is a GLP-1 receptor agonist with 97% homology to human GLP-1. A C-16 fatty acid (palmitic acid) attached via a glutamic acid spacer enables albumin binding, extending its half-life to 13 hours for once-daily dosing.
Research Profile
Liraglutide is an acylated analog of human GLP-1(7-37) with a single amino acid substitution (Arg34Lys) and attachment of a C-16 palmitic acid via a glutamic acid linker at Lys26. This palmitoylation promotes self-association at the injection site and albumin binding in plasma, together extending its half-life to approximately 13 hours. Liraglutide stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite through central GLP-1 receptor activation. It was the first GLP-1 RA approved for both diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Clinical trials demonstrated sustained weight loss of 5-8% and cardiovascular risk reduction in type 2 diabetes patients.
Technical Details
- Chemical Formula
- C172H265N43O51
- Synonyms
- Liraglutide, Victoza, Saxenda, NN2211
- Molecular Weight
- 3751.20 g/mol
- CAS Number
- 204656-20-2
- Appearance
- Lyophilized White Powder
- Purity
- >98% (HPLC Verified)
- Shelf Life
- 36 months (Store at 2-8°C)